RegeneRx Biopharmaceuticals, Inc. Receives Australian Patent for the Use of TB4 to Treat Central Nervous System Diseases and Tissue Damage

ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) announced today that the Company has been issued an Australian Patent for treating, preventing or restoring tissue deterioration, injury or damage due to a neuro-muscular or neuro-degenerative disease. The patent will expire in 2026. RegeneRx has similar patents pending in numerous other countries, including in the U.S. and throughout Asia and Europe.